HeartWare International Inc  

(Public, NASDAQ:HTWR)   Watch this stock  
Find more results for HTWR
57.82
+0.06 (0.10%)
After Hours: 57.81 -0.01 (-0.02%)
Jul 25, 5:02PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 57.70 - 57.83
52 week 25.01 - 94.15
Open 57.75
Vol / Avg. 167,634.00/921,996.00
Mkt cap 1.01B
P/E     -
Div/yield     -
EPS -4.37
Shares 17.54M
Beta 0.35
Inst. own 102%
Sep 7, 2016
HeartWare International Inc at Wells Fargo Securities Healthcare Conference Add to calendar
Aug 10, 2016
HeartWare International Inc at Canaccord Genuity Growth Conference Add to calendar
Jul 28, 2016
Q2 2016 HeartWare International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 8, 2016
HeartWare International Inc at Goldman Sachs Global Healthcare Conference
Jun 3, 2016
HeartWare International Inc Annual Shareholders Meeting (Estimated)
Jun 2, 2016
HeartWare International Inc Annual Shareholders Meeting
May 10, 2016
HeartWare International Inc at Bank of America Merrill Lynch Health Care Conference
May 4, 2016
Q1 2016 HeartWare International Inc Earnings Release
May 4, 2016
Q1 2016 HeartWare International Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -31.70% -26.29%
Operating margin -27.64% -13.45%
EBITD margin - -11.92%
Return on average assets -15.83% -16.59%
Return on average equity -38.47% -36.66%
Employees 625 -
CDP Score - -

Address

500 Old Connecticut Path
FRAMINGHAM, MA 1701
United States - Map
+1-508-7390873 (Phone)
+1-508-7390948 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery. The HVAD System features the centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. It develops MVAD System, a miniaturized device. The CircuLite Surgical System is designed to be implanted through a right, mini-thoracotomy procedure and does not require a sternotomy or cardiopulmonary bypass.

Officers and directors

Charles Raymond Larkin Jr. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Douglas Evan Godshall M.B.A. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Seth L. Harrison M.D. Deputy Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Peter F. McAree Chief Financial Officer, Senior Vice President, Treasurer
Age: 50
Bio & Compensation  - Reuters
Jeffrey Adrian LaRose Executive Vice President, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Lawrence Knopf Senior Vice President, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
James Schuermann Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Mark H Strong Senior Vice President, Research and Development and Quality Assurance
Age: 43
Bio & Compensation  - Reuters
Robert E Yocher Senior Vice President, Regulatory Affairs
Age: 64
Bio & Compensation  - Reuters
Katrin Leadley M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters